Cargando…
Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials
BACKGROUND: SOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we report safety and immunogenicity from phase I and IIa clinical trials using two-doses of SOBERANA 02 and three-doses (homologous) or hete...
Ejemplares similares
-
Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults
por: Toledo-Romani, María Eugenia, et al.
Publicado: (2022) -
A cell-based ELISA as surrogate of virus neutralization assay for RBD SARS-CoV-2 specific antibodies
por: Pi-Estopiñan, Franciscary, et al.
Publicado: (2022) -
A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial
por: Chang-Monteagudo, Arturo, et al.
Publicado: (2021) -
A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles
por: Santana-Mederos, Darielys, et al.
Publicado: (2021) -
A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity
por: Pérez-Rodríguez, Sonia, et al.
Publicado: (2022)